Top

CNS Drugs

Published in:

01-07-2010 | Adis Profile Report

Escitalopram in the treatment of major depressive disorder in adolescent patients

Profile report

Authors: Lily P. H. Yang, Lesley J. Scott

Published in: CNS Drugs | Issue 7/2010

Excerpt

Depression is a recurrent and highly heterogeneous psychiatric disorder that impacts on social, emotional and cognitive functioning.[2,3] More specifically, major depressive disorder (MDD) is characterized by a mood change to sadness or irritability, and is accompanied by other changes such as sleep or appetite disturbances, with suicidality as one of the main complications.[2‐4] The estimated prevalence of MDD is ≈2% in children and 4–8% in adolescents.[2] …

Yang LPH, Scott LJ. Escitalopram: in the treatment of major depressive disorder in adolescent patients. Pediatr Drugs 2010; 12(3): 155–62CrossRef

Birmaher B, Brent D, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. AACAP Work Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 2007 Nov; 46(11): 1503–26CrossRef

Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008 Jan 3; 358(1): 55–68PubMedCrossRef

American Psychiatric Association. Mood disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 317–92

Adams SM, Miller KE, Zylstra RG. Pharmacologic management of adult depression. Am Fam Physician 2008 Mar 15; 77(6): 785–92PubMed

Bylund DB, Reed AL. Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs? Nuerochem Int 2007 Oct; 51(5): 246–53CrossRef

Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009 Aug 11; 339: b2880PubMedCrossRef

Cohen D, Deniau E, Maturana A, et al. Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials. PLoS One 2008 Jul 9; 3(7): e2632PubMedCrossRef

Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2007 Jul 18; (3): CD004851

10.

Tsapakis EM, Soldani F, Tondo L, et al. Efficacy of antidepressants in juvenile depression: meta-analysis [published errata appear in Br J Psychiatry 2008 Aug; 193 (2): 169, and 2008 Oct; 193 (4): 346]. Br J Psychiatry 2008 Jul; 193(1): 10–7PubMedCrossRef

11.

Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and ongoing management [published erratum appears in Pediatrics 2008 Jan; 121 (1): 227]. Pediatrics 2007 Nov; 120(5): e1313–26PubMedCrossRef

12.

National Institute for Health and Clinical Excellence. Depression in children and young people: identification and management in primary, community and secondary care (clinical guideline 28) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG028NICEguideline.pdf [Accessed 2010 Mar 10]

13.

Forest Laboratories, Inc. Forest Laboratories, Inc. announces FDA approval of Lexapro(R) for the treatment of major depressive disorder in adolescents [online]. Available from URL: http://www.frx.com/news/PressRelease.aspx?ID=1268211 [Accessed 2010 Mar 10]

14.

Forest Laboratories, Inc. Lexapro® (escitalopram oxalate) tablets and oral solution: US prescribing information [online]. Available from URL: http://www.frx.com/pi/lexapro_pi.pdf [Accessed 2010 Mar 10]

15.

Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005; 65(16): 2379–404PubMedCrossRef

16.

Emslie GJ, Ventura D, Korotzer A, et al. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009 Jul; 48(7): 721–9PubMedCrossRef

17.

Forest Laboratories, Inc. A double-blind, fixed-dose extension study of escitalopram in pediatric patients with major depressive disorder [study no. SCT-MD-32A] [online]. Available from URL: http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_SCT-MD-23-23A_final.pdf [Accessed 2010 Mar 10]

18.

Wagner KD, Jonas J, Findling RL, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006 Mar; 45(3): 280–8PubMedCrossRef

Title: Escitalopram in the treatment of major depressive disorder in adolescent patients
Profile report
Authors: Lily P. H. Yang
Lesley J. Scott
Publication date: 01-07-2010
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 7/2010
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11204690-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Escitalopram in the treatment of major depressive disorder in adolescent patients

Profile report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2010

Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine

Antidepressant-induced hyperprolactinaemia

Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’ as an indicator

Medication errors in psychiatry

Lafora disease

Pharmacotherapy of bipolar disorder in children and adolescents